January 25, 2012 — Terumo Cardiovascular Systems entered into an exclusive agreement with LAAx Inc. to distribute the TigerPaw System II, a left atrial appendage (LAA) closure device in the United States.
The TigerPaw System II is indicated for occlusion of the left atrial appendage under direct visualization, in conjunction with other open cardiac procedures. It is new to the market following successful completion of a clinical trial. During its clinical trial, the TigerPaw System II provided 100 percent occlusion at both post-op and at 90 days.
"Terumo's broad distribution network will be a tremendous asset," said Bill Wheeler, president and CEO of LAAx. "We will work together to get the TigerPaw System II into the hands of cardiac surgeons who have not yet had access to a clinically proven, 100 percent occlusive left atrial appendage (LAA) closure device … Risk mitigation is an important consideration for every cardiac surgeon who considers 100 percent occlusion to be the only acceptable medical outcome for LAA occlusion technologies."
For more information: www.terumo-cvs.com
October 23, 2024 
